Eli Lilly expects to launch the drug for OSA at the beginning ... The index is used to evaluate the severity of obstructive sleep apnea and the effectiveness of treatments for the condition. Disease ...

Key Takeaways Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound ...

The FDA has cleared Eli Lilly’s obesity drug Zepbound as the first treatment for obstructive sleep apnea in the U.S.

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity.

The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in combination with diet and exercise.

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...

Sleep apnea, a sleep disorder typically managed with a medical device that aids in breathing, now has its first FDA-approved drug therapy, an Eli Lilly medicine initially developed as a treatment ...

Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep apnea.

Eli Lilly expects to launch the drug for OSA at ... The index is used to evaluate the severity of obstructive sleep apnea and the effectiveness of treatments for the condition.